PLEASANTON, Calif., Feb. 12, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided outlook for 2025.Recent Updates Revenue was $165.0 million for the fourth quarter and $610.8 million for the full year of 2024, representing 10% and 1% decreases over the corresponding periods of 2023. In collaboration with the Chan Zuckerberg Initiative (CZI) and Ultima Geno ...

Wall Street analysts expect 10x Genomics (TXG) to post quarterly loss of $0.32 per share in its upcoming report, which indicates a year-over-year increase of 22%. Revenues are expected to be $158.14 million, down 14% from the year-ago quarter.The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Before a company announces ...

Core Insights - The Chan Zuckerberg Initiative (CZI) has launched the Billion Cells Project to create a dataset of one billion cells aimed at enhancing AI model development in biology [1][2] - The project will provide critical data for understanding cellular behavior, gene function, and the genetic drivers of human diseases, ultimately guiding drug development [5][6] Project Overview - The Billion Cells Project is a collaboration involving CZI, 10x Genomics, Ultima Genomics, and leading researchers, focusing on generating data at an unprecedented scale [1][4] - The initiative aims to produce a cohesive dataset that will improve the training of AI models and facilitate transformative discoveries in precision medicine and functional genomics [2][3] Technological Innovations - The project will utilize 10x Genomics' Chromium GEM-X technology, which enhances sensitivity, throughput, and data quality for single-cell analysis [5][6] - Sequencing will be conducted on Ultima Genomics' UG 100™ platform, known for its ultra-high throughput and low-cost capabilities, making it suitable for large-scale genomic data generation [6][8] Collaboration and Impact - CZI's approach emphasizes collaboration among industry partners to accelerate data generation and knowledge sharing across various biological domains [4][8] - The project is expected to set a precedent for future collaborations in the life sciences sector, aiming to deliver significant advancements in understanding human biology [8]

Torex Gold Provides Q4 2024 Update on Media Luna ProjectConstruction substantially complete and first copper concentrate on track for MarchFebruary 04, 2025 6:00 PM EST | Source: Torex Gold Resources Inc.(All amounts expressed in U.S. dollars unless otherwise stated)Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) provides a Q4 2024 update on the development of its Media Luna Project ("Media Luna"). Unless otherwise stated, ...

PLEASANTON, Calif., Jan. 28, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Wednesday, February 12, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release ...

Torex Gold Provides 2025 Operational Guidance and Updated Five-Year Production OutlookOn track to return to positive free cash flow mid-year as Media Luna ramps upJanuary 14, 2025 6:00 PM EST | Source: Torex Gold Resources Inc.(All amounts expressed in U.S. dollars unless otherwise stated)Toronto, Ontario--(Newsfile Corp. - January 14, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) provides 2025 operational guidance as well as an updated five-year production outlook fo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K ______________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2025 10x Genomics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) Delaware 001-39035 45-5614458 (Commission File Number) (IRS Employer Identification No.) Washington, D.C. 20549 ______________________ 6230 Stoneridge Mall R ...

Company Performance - The company reported preliminary, unaudited FY 2024 revenue of approximately $611 million and Q4 2024 revenue of approximately $165 million, representing 9% sequential growth [4] - Q4 2024 revenue of $165 million showed a 10% decrease compared to the corresponding prior year period [10] - FY 2024 revenue of $610.8 million represented a 1% decrease from the prior year [10] - The company's cumulative instruments sold increased to over 7,000 by the end of 2024, including over 5,800 Chromium instruments, over 800 Visium instruments, and over 400 Xenium instruments [10] - Cash, cash equivalents, and marketable securities stood at approximately $393 million as of December 31, 2024 [10] Revenue Breakdown - Q4 2024 instruments revenue was approximately $24.4 million, showing 28% sequential growth but a 37% decrease compared to the prior year period [10] - Q4 2024 consumables revenue was approximately $133.5 million, with 6% sequential growth but a 5% decrease compared to the prior year period [10] - Q4 2024 services revenue was approximately $7.1 million, showing 12% sequential growth and 35% growth over the prior year period [10] - FY 2024 instruments revenue was approximately $92.7 million, a 25% decrease from the prior year [10] - FY 2024 consumables revenue was approximately $493.4 million, representing 3% growth over the prior year [10] - FY 2024 services revenue was approximately $24.6 million, showing 57% growth over the prior year [10] Product-Specific Revenue - Q4 2024 Chromium instruments revenue was approximately $10.9 million, while Spatial instruments revenue was approximately $13.4 million [10] - Q4 2024 Chromium consumables revenue was approximately $97.7 million, while Spatial consumables revenue was approximately $35.8 million [10] - FY 2024 Chromium instruments revenue was approximately $35.2 million, while Spatial instruments revenue was approximately $57.5 million [10] - FY 2024 Chromium consumables revenue was approximately $372.3 million, while Spatial consumables revenue was approximately $121.1 million [10] Company Overview - The company is a life science technology firm focused on accelerating the mastery of biology and advancing human health [7] - Its integrated solutions include instruments, consumables, and software for single cell and spatial biology [7] - The company's products support breakthroughs in oncology, immunology, neuroscience, and other fields [7] Investor Relations - The company will participate in the 43rd Annual J P Morgan Healthcare Conference, with a live webcast available on January 13, 2025 [1] - The company discloses material non-public information through SEC filings, its website, press releases, conference calls, webcasts, and social media accounts [3]

Torex Gold Delivers on Full-Year Production Guidance2024 marks the sixth consecutive year production guidance has been achievedJanuary 08, 2025 6:00 PM EST | Source: Torex Gold Resources Inc.Toronto, Ontario--(Newsfile Corp. - January 8, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports fourth quarter gold production of 103,795 ounces ("oz") and full-year gold production of 452,523 oz, within the Company's revised guidance range of 450,000 to 470,000 oz (original ...

Toronto, Ontario--(Newsfile Corp. - December 17, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports that the Director General of Mines under the Federal Ministry of Economy has lifted the temporary suspension notice and allowed for all activities within the Morelos Complex to resume.Jody Kuzenko, President & CEO of Torex, stated:"Following notification that the temporary suspension has been lifted by the Director General of Mines, all production and development activities at th ...